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BACKGROUND: Central obesity is known as a risk factor for type 2 diabetes mellitus (T2DM). Its development is influenced by many factors such as 
a progressive failure of pancreatic beta cell function. The 
beta cells increase their function to secret insulin along 
T2DM development to compensate before it becomes 
exhausted. Zinc (Zn) plays a crucial role in beta cell 
function and insulin secretion. The majority of Zn in serum 
are bound to protein which is not readily available interact 
with cells. The free Zn in serum has been suggested as being 
more representative than total Zn in beta cell function. This 
research aimed to investigate the correlation between serum 
free Zn and homeostasis model assessment for beta cell 
function (HOMA-B)  and to predict the pancreatic beta cell 
function in the development of T2DM.
METHODS: This study was designed as an observational 
with a cross-sectional approach. The subjects were centrally 
obese men aged 30-50 years and who had met the inclusion 
and exclusion criteria from the screening tests. Control 
subjects were lean men without T2DM. Serum free Zn and 
serum total Zn were measured by using inductively coupled 
plasma-mass spectrometry (ICP-MS).
RESULTS: There was positive correlation between serum 
free Zn and HOMA-B (R=0.361, p-value<0.001) but there 
was  no  correlation  between  serum  total  Zn  and HOMA-B 
(R=-0.062, p-value=0.563). This study found that if the 
concentration of serum free Zn >1.7 ug/dL in central obese 
men was suggested as an excessive function of pancreatic 
beta cell and as an early warning before its exhausted.
CONCLUSION: This study suggested that serum free Zn 
had  a  correlation  with  beta  cell  function  and  had a 
predictive ability for beta cell excessive function before its 
exhausted.
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Abstract
Introduction
Central obesity is known as a risk factor for type 2 diabetes 
mellitus (T2DM) which is preceded by insulin resistance.
(1,2) Besides insulin resistance, the other indispensable 
factor is a failure of the pancreatic beta cell to secrete 
sufficient insulin to maintain blood glucose concentration.
(3) Current findings from Genome-Wide Association Studies 
(GWAS) have shown that many gene variations increase 
the T2DM risk that cause pancreatic beta cell dysfunction 
rather than insulin resistance.(4) Beta cell dysfunction also 
recognized in pathogenesis and progression of T2DM.(5)
 At initial phase of T2DM development, especially in 
prediabetes, pancreatic beta cells compensate by increasing 
secretion to meet the demand of insulin needed to control 
blood glucose concentration. The compensation is most 
common with the insulin resistance due to obesity which 
is accompanied by the increase of total insulin secretion.(6) 
Much of the rise in insulin secretion is a result of an increase 
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of beta cell mass. In insulin resistance-induced obesity, the 
increase of beta cell mass probably due to increased of beta 
cell numbers.(7,8)
 The insulin secretion process involves many factors, 
including the presence of biometals. One of the essential 
biometals is zinc (Zn) which plays a critical function in the 
production of secretory granules for insulin secretion.(9) 
A  high  concentration  of  Zn  is  required  in  the  beta 
cell for insulin crystallization, maturation, and secretion. 
Furthermore, Zn is essential for the appropriate insulin 
synthesis, storage, and structural stability as well. Serum 
Zn deficiency is common in T2DM and has been suggested 
as a risk factor for the disease.(10) The exact molecular 
mechanism of Zn in T2DM remains unclear. Role of Zn 
in metabolism occurs inside of the cell. Its concentration 
inside is higher than the outside and this difference in 
concentration is maintained by Zn homeostasis system.
(11) Zn homeostasis is a dynamic system with the pool 
approximately 0.1% of total Zn concentration in the body 
and  98%  of  Zn  in  the  blood  is  bound  to  the  albumin 
and not ready to interact with cells including pancreatic beta 
cells.(12) 
 The  concentration  of  serum  free  Zn  was  expected 
more  representative  than  serum  total  Zn  in  the  pancreatic 
beta cell function and it depicted the natural history of 
pancreatic beta cell compensation before its exhausted. 
Currently, there is no data available of serum free Zn 
concentration profile and its role in pancreatic beta cell 
function. The objective of this research was to investigate 
the correlation of serum free Zn concentration with the beta 
cell function and predict the excessive beta-cell function in 
central obese-men.
Methods
This was a cross-sectional, observational study. The subjects 
of this study were 70 central obese men, aged 30-50 years 
old who were recruited from Jakarta, Bandung, Semarang, 
and Bogor. They had waist circumference ≥90 cm according 
to the International Obesity Task Force (IOTF) criteria.(13) 
HbA1c concentration was used to determine diabetes status 
according to the American Diabetes Association (ADA) 
criteria. Diabetes diagnosed when HbA1c concentration 
≥6.5%, prediabetes considered when HbA1c concentration 
was 5.7-6.4%, and non-diabetes stated when HbA1c 
concentration <5.7%.(14) HbA1c measurement was using 
high performance liquid chromatography (HPLC) (Variant 
Turbo, Biorad, USA) which is certified by National 
Glycohemoglobine Standardization Program (NGSP). The 
control group consisted of 20 lean men aged 30-50 years old 
with a waist circumference <90 cm and without T2DM. The 
number of samples of this study was calculated by using the 
formula for a quantitative variable.(15) 
 Subjects who had the following conditions were 
excluded from the study: acute inflammation marked by 
hsCRP concentration >10 mg/L, impaired renal function 
marked by estimated glomerulus filtration rate <60 mL/
min/1.73 m2, taken zinc, iron, and copper supplement in 
last 1 month, and impaired liver function marked by serum 
glutamic oxaloacetic transaminase (SGOT) and serum 
glutamic pyruvic transaminase (SGPT) concentration more 
than 2 times upper limit or reference value. Laboratory 
analysis for screening test were done by Prodia Clinical 
Laboratory. Serum free and total Zn measurement were 
done and validated by Mass Spectrometry Laboratory in 
Prodia Clinical Laboratory. Serum free and total Zn were 
measured by inductively coupled plasma mass spectrometry 
(ICP-MS). Beta cell function was determined by using 
the homeostasis model assessment beta cell (HOMA-B) 
which calculated from fasting blood glucose and insulin 
concentration.(16) This research protocol was approved 
by Universitas Padjadjaran Ethics Commision No: 1039/
UN6.C.10/PN/2017. 
 Materials used in this research were human serum 
collected using metal free vacuum tube, Vivaspin 500 
Ultrafilter 10 kDa MWCO (Sartorius, Gottingen, Germany), 
Nitric Acid 65% supra pure grade (Merck, Darmstadt, 
Germany), ultra pure water 18.2 Mega Ohm, Zinc standard 
(Merck), Indium Standard (Merck), Centrifuge (Thermo 
Scientific, Massachusetts, USA), and ICP-MS (Agilent 
Technologies, California, USA). Data was processed by 
using SPSS version 24 for Windows (SPSS Inc, Chicago, 
USA).  The  level  of  significance  was  0.05  for  data 
analysis. 
The initial number of subject recruited was 120 subjects 
including control. Of this number, 70 men central obesity 
were admitted into the study. Twenty lean men who 
did not have T2DM served as control subjects. Subject 
characteristics based on the screening test are shown in 
Table 1. 
 There  was  a  significant  correlation  between  free 
serum Zn and HOMA-B but not with total serum Zn as 
shown in Table 2. 
Results
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Lean                   
(n = 20)
Non-DM Non-DM Pre-DM DM
100% 52.80% 31.40% 15.70%
Age (years old) 39 ± 6 39 ± 6 40 ± 6 43 ± 5 0.191
Waist Circumference (cm) 81 ± 7 103 ± 9 106 ± 9 106 ± 9 <0.001*
SGOT (U/L) 20 ± 5 25 ± 8 26 ± 9 26 ± 8 0.045*
SGPT (U/L) 20 ± 10 36 ± 15 40 ± 20 39 ± 23 <0.001*
HbA1c (%) 5.2 ± 0.2 5.3 ± 0.3 5.9 ± 0.2 9.1 ± 2.3 <0.001*
eGFR (mL/min/1.73 m2) 98 ± 11 101 ± 13 104 ± 10 104 ± 14 0.248
hsCRP (mg/L) 0.8 ± 0.6 3.1 ± 2.1 3.6 ± 2.7 5.0 ± 3 <0.001*
Free Zn (ug/dL) 1.4 ± 0.9 1.9 ± 1.2 2.4 ± 1.5 1.3 ± 1.0 0.040*
Total Zn (ug/dL) 83 ± 14 79 ± 10 80 ± 11 75 ± 12 0.759
HOMA-B (%) 66 ± 31 167 ± 99 194 ± 88 110 ± 88 <0.001*
Variables
Central-Obese                                                                                              
(n = 70)
p -value
Table 1. Subjects characteristic based on screening tests.
*Significant in 95% confident interval using Kruskal-Wallis test.
Correlation 
Coefficient p -value
Serum Free Zn 0.361 < 0.001*
Serum Total Zn -0.062 0.563
Variables
HOMA-B
*Significant in 95% confident interval using Spearman’s 
correlation.
Table 2. Correlation of serum Zn free and Zn total 
with HOMA-B.
 HOMA-B classification depicts the function of the 
pancreatic beta cell. HOMA-B reference value was 70-150%. 
HOMA-B values of <70% suggest as beta cell dysfunction 
if  it  occurs  in  the  T2DM subject  (17)  and when the 
HOMA-B value >150% in central obesity is suggested  as 
beta cell excessive function to secreting insulin. Figure 1 
shown the median of serum free Zn concentration in the 
HOMA-B classification. Serum free Zn concentration in 
T2DM disease development had a similar pattern with the 
HOMA-B as shown in Figure 2.
 ROC analysis showed that serum free Zn concentration 
of >1.7 ug/dL in central-obese men suggested there was an 
excessive function of beta cell due to its compensation to 
secreted insulin in high concentration (AUC: 0.639, 95% 
CI: 0.521-0.757, p-value: 0.025, sensitivity: 64%, and 
specificity: 68%).
Discussion
The role of Zn in pathogenesis and disease development 
of T2DM through inflammation mechanism has been 
established.(8) Of the 70 centrally obese men recruited for 
this study, 52.8% were not suffering from T2DM, 31.4% 
were prediabetics, and 15.7% were T2DM. In centrally 
obese subjects with who were non-diabetic and pre-
diabetic, the concentration of serum free Zn was higher than 
in lean subjects as shown in Table 1. There is no difference 
for serum total Zn concentration between those groups. 
T2DM pathogenesis is also caused by chronic inflammation 
in the adipose tissue, liver, muscle, and pancreas as well. 
Chronic inflammation is the process when increasing 
amounts of proinflammatory cytokine reaches the pancreas.
(18) This theory was in line with the result of this research 
that showed increased high-sensitivity C-reactive protein 
(hsCRP) in central obesity than in lean (3.5±2.4 vs. 0.8±0.6 
mg/L, p-value<0.0001 in 95% confidence interval). In 
inflammation, Zn influx into cells is higher than in normal 
condition, and the ready state of Zn before its entered the 
cell is the free form.(19) Moreover, the binding capacity of 
a carrier protein to Zn decreased due to inflammation and 
suggested as a natural response of the cell.(12)
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Figure 1. Serum free Zn concentration in HOMA-B 
classification.
 Besides inflammation, T2DM progression is also 
marked by the increase of pancreatic beta cell function as a 
compensatory response for the high demand of insulin. Beta 
cell function in this study was measured by the HOMA-B 
calculation. Zn also plays a critical role in the activity of 
beta cell for insulin secretion through its homeostasis.(9) 
This research showed that there was a positive correlation 
between serum Zn free and HOMA-B but not with serum 
total Zn as shown in Table 2. It suggested that the demand 
of free Zn increased due to beta-cell activity and probably 
with beta cell mass as well as shown in Figure 1. Figure 1 
showed that there was a pattern in every level of HOMA-B. 
In low HOMA-B (<70%), serum free Zn concentration 
was lower than in normal HOMA-B (70%-150%) and 
also high HOMA-B (>150%). High Zn free concentration 
in excessive function of the beta cell also linked with the 
theory that stated that Zn deficiency is a risk factor for 
T2DM progression.(10) Serum Zn deficiency is thought to 
occur because of the from high demand of Zn from cells 
including the pancreatic beta cells. 
 There was a similar pattern of serum free Zn and 
HOMA-B  in  the  development  of  T2DM  as  shown  in 
Figure 2. There was an increase of free Zn which reached the 
maximum  at  the  prediabetes  and  decreased  in  the  T2DM 
condition. In T2DM, the beta cell is exhausted and loses its 
mass, and as a final result, insulin secretion decreased.(20) 
Based on that profile, serum free Zn concentration had a high 
potential to predict the excessive function of pancreatic beta 
cell in central-obesity. Beta cell excessive function occurred 
in prediabetes condition, and if that signal is ignored, T2DM 
progression will cause the beta cell dysfunction. Receiver 
operating characteristic (ROC) analysis showed that if the 
concentration of serum free Zn concentration of centrally 
Conclusion
There was a positive correlation between serum free Zn 
concentration with beta cell function, and if the concentration 
of free Zn more than 1.7 ug/dL in central obesity, suggested 
as excessive function of pancreatic beta-cell. 
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Figure 2.  Concentration of serum free Zn and HOMA-B in the 
development of T2DM. A: median of serum free Zn concentration; 
B: median of HOMA-B.
obese men more than 1.7 ug/dL, it is suggested that there 
is the beta cell ecsessive function with 64% sensitivity and 
68% specificity. It is crucial to monitor the concentration 
of serum free Zn in central for the better management of 
T2DM development. Serum free Zn concentration is also 
considered as a more powerful marker to predict the beta 
cell function and T2DM development than serum total Zn 
that is routinely measured. 
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